Comment

  • 22 May 2018

    PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...

  • 8 May 2018

    Barriers impede biosimilar market entry into the US

    Back in 2010, the FDA implemented the Biologics Price Competition and Innovation Act (BPCIA) as part of the Affordable Care Act (ACA), which created an abbreviated pathway for biosimilar drug...

  • 26 April 2018

    Colorectal cancer pipeline insight

    Within the GlobalData Pharma Intelligence Center, there are profiles of many drug candidates that focus on the prevention and treatment of colorectal cancer.